Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Arthritis
Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome
June 30th, 2009
Proteolix, Inc. announced that in an article published in Nature Medicine, Proteolix's selective immunoproteasome inhibitor PR-957 was shown to block disease progression in mouse models of rheumatoid arthritis in a dose-dependent manner and to completely eliminate visible signs of disease at the highest dose. The anti-inflammatory effect induced by PR-957 was rapid and long-lasting, lowering expression of multiple inflammatory mediators, including TNF-a and IL-6. Disease regression was evident 24 hours after dosing and a complete amelioration of disease was achieved with a single dose. When compared to anti-TNF-a therapy (etanercept), PR-957 mediated a more rapid resolution of clinical...
Source: Cancer Weekly (2009-06-30)
|
